Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have received an average rating of “Moderate Buy” from the five analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $8.3333.

A number of equities research analysts have issued reports on AUTL shares. Wall Street Zen lowered shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a research report on Wednesday, September 24th.

Institutional Trading of Autolus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Marex Group plc acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth $28,000. Caitong International Asset Management Co. Ltd bought a new stake in Autolus Therapeutics in the third quarter worth $46,000. R Squared Ltd bought a new stake in Autolus Therapeutics in the second quarter worth $50,000. Invesco Ltd. increased its position in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after buying an additional 11,381 shares during the last quarter. Finally, Delaney Dennis R bought a new position in Autolus Therapeutics during the second quarter valued at about $55,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Trading Up 0.6%

Shares of NASDAQ AUTL opened at $1.57 on Friday. Autolus Therapeutics has a one year low of $1.11 and a one year high of $2.80. The business has a 50-day moving average price of $1.48 and a two-hundred day moving average price of $1.81. The firm has a market capitalization of $417.84 million, a PE ratio of -1.89 and a beta of 2.01.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%.The company had revenue of $21.19 million during the quarter, compared to analysts’ expectations of $21.08 million. Research analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.